Armata Pharmaceuticals, Inc.
AP-SA02
complicated S. aureus bacteremia
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on AP-SA02 for complicated S. aureus bacteremia is expected Date TBD.
Primary source
· SEC 8-K
verified 12h ago
“If successful, AP-SA02 has the potential to offer an important new treatment option for patients facing this serious and often life-threatening infection.”